CCM Data & Primary Intelligence
Market of Paclitaxel Injection in China The first edition August 2010
Researched & Prepared by:
Guangzhou CCM Information Science & Technology Co., Ltd. Guangzhou, P. R. China Website: www.cnchemicals.com Tel: +86-20-3761 6606 Fax: +86-20-3761 6968 Email: econtact@cnchemicals.com
Website: http://www.cnchemicals.com Tel: +86-20-3761 6606
Email: econtact@cnchemicals.com Fax: +86-20-3761 6968
CCM Data & Primary Intelligence Description: Nowadays, paclitaxel injection has been widely used to cure cancers like non-small cell lung cancer, breast cancer, and ovarian cancer, etc. Besides, paclitaxel injection has become one of the best selling anticancer drugs in the world. The paclitaxel injection production values had reached USD67.21 million for China in 2009, accounting for 10% of total in world. China has become one of the most important consumption markets in the world. Chinese paclitaxel injection industry has witnessed significant development from 2005～2009. On one hand, since 2005, Chinese government has issued a series of policies related to China’s pharmaceutical industry like healthcare reform. How do they influence the paclitaxel injection industry? On the other hand, paclitaxel injection has enjoyed the second largest market share in natural anticancer drugs in China, thanks to its good clinical effect and less side effect. What is the current production and consumption situation in China? For China paclitaxel injection manufacturers, active pharmaceutical ingredient (paclitaxel APIs) plays an important role. Owing to the increasing cultivated planting yew, price of APIs has declined gradually, thus pushing down the price of paclitaxel injection price. Besides, by the end of Jun. 2010, Chinese government has adjusted export tax rebate rate of paclitaxel injection. How did the paclitaxel APIs and paclitaxel injection manufacturers respond to this change? In 2009, Sichuan Jiufeng Pharmaceutical Co., Ltd. (Sichuan Jiufeng), the largest producer of paclitaxel injection in China, has increased its output of paclitaxel injection greatly because of the great demand, and then what is the performance of Sichuan Jiufeng in 2010? What’s more, paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms. How do the pharmaceutical distribution companies distribute the paclitaxel injection, and how does the medicine bidding and purchase platforms for paclitaxel injection are operated? Besides the aspects mentioned above, what is the production distribution of paclitaxel APIs? What is the development trend of China’s paclitaxel injection? CCM has carried out in-depth research and analysis on each active producer, as well as the whole industry to figure out these questions. In this report, you can obtain info about: - Production distribution of paclitaxel APIs - General situation of paclitaxel injection production and its manufacturers - Top 2 pharmaceutical distribution companies in China - Medicine bidding and purchasing platforms - Import and export paclitaxel injection analysis, as well as paclitaxel APIs export analysis - Consumption situation of paclitaxel injection - Government policy for paclitaxel injection and quality standards of paclitaxel injection - circulation model of paclitaxel injection in China With the information covered in the report, readers can see the general production and consumption situation, circulation model, as well as APIs supply situation for China paclitaxel injection manufacturers in China, which are beneficial for the investors’ decision making. Main content: No.
Content
Website: http://www.cnchemicals.com Tel: +86-20-3761 6606
Page
Email: econtact@cnchemicals.com Fax: +86-20-3761 6968
CCM Data & Primary Intelligence I I-1 I-2 II II-1 II-2 II-3 II-4 III IV IV-1 IV-1.1 IV-1.2 IV-1.3 IV-2 V V-1 V-2 V-3 VI VI-1 VI-1.1 VI-2 VI-2.1 VI-2.1.1 VI-2.1.2 VI-2.1.3 VI-2.2 VI-3 VI-3.1 VI-3.2 VII VII-1 VII-2 VIII IX IX-1 ... IX-10
Executive summary Development of policy environment for paclitaxel injection in China Regulation in GMP about paclitaxel injection Regulation about paclitaxel injection in CP 2000 Production of paclitaxel injection in China Production data from 2005 to 2009 Regional distribution of paclitaxel injection production Summary of paclitaxel injection manufacturers in China, 2008&2009 Competition analysis of paclitaxel injection producers Production of paclitaxel APIs in China China’s paclitaxel injection distribution model Pharmaceutical distribution business in China Development history of pharmaceutical distribution business in China China’s major regional market share of pharmaceutical distribution business Sales value and concentration of pharmaceutical distribution business in China Introduction to distribution of paclitaxel injection with Chinese characteristic China’s medicine bidding and purchasing platform Background of medicine bidding and purchasing platform Flow chart of medicine bidding and purchasing platform Top two pharmaceutical distribution companies Consumption of paclitaxel injection in China Overview of anticancer drugs in China Consumption situation of natural anticancer drugs Consumption situation of paclitaxel injection Consumption in end-user sectors NSCLC Breast cancer Ovarian cancer Distribution of paclitaxel injection consumption in top five provinces Consumption potential analysis of paclitaxel injection in next 5 years Influencing factors for consumption Forecast consumption of paclitaxel injection in China, 2010-2015 Import and export situation in 2009 Import and export situation for paclitaxel injection Export situation for paclitaxel APIs Resource of yew in China Profile of major manufacturers of paclitaxel injection in China Sichuan Jiufeng Pharmaceutical Co., Ltd. Youcare Pharmaceutical Group Co., Ltd.
1 3 4 6 7 7 7 10 12 13 17 17 17 19 20 21 23 23 23 24 27 27 28 28 30 30 31 32 33 34 34 35 38 38 39 41 44 44 0 50
Executive summary: China started clinical application of paclitaxel injection in 1994 with exported products, and then achieved industrialized production when Yunnan Hande Bio-tech Co., Ltd., the first paclitaxel injection producer in China, entered this market. Currently, China is one of the leading consumption areas in the world, capturing over xx% consumption of global market share.
Website: http://www.cnchemicals.com Tel: +86-20-3761 6606
Email: econtact@cnchemicals.com Fax: +86-20-3761 6968
CCM Data & Primary Intelligence Besides in China, the consumption of paclitaxel injection takes up xx% of total antineoplastic medicines, and the share tends to increase. And since 2005, China has become one of the largest paclitaxel injection production bases in the world with more and more producers entering the market because of the increasing demand, and its paclitaxel injection production value has increased from USDxx million in 2005 to USDxx million in 2009, with CAGR of xx% for 2005 ~ 2009. But only some of the paclitaxel injection manufacturers have expanded to foreign market, such as Beijing Double Heron Pharmaceutical Co., Ltd. and Youcare Pharmaceutical Group Co., Ltd., but only in Southeast Asia and Middle East countries like Pakistan (PAK), Philippine, etc. Most of the companies do their business mainly in the domestic market due to the high quality threshold for other countries, especially for developed countries. In 2009, China’s paclitaxel injection export value has reached USDxx through China customs. As for the import, in 2009, Guangdong Zhongjian Medicine Co., Ltd., Hainan Gaoxiang Medicine Co., Ltd. and Bristol-Myers Squibb (China) are the three main paclitaxel injection importers in China with total import value of USDxx. Paclitaxel injection in the treatment of the cancer patients is made from paclitaxel APIs which is extracted from yew. China is one of the largest yew production countries in the world with xx million of planting amount in 2009, accounting for xx % of world’s total. Paclitaxel injection industry does harm to rare plant – Yew, due to little content of paclitaxel in yew and yew’s long growth cycle. Under stricter environmental protection policies, some small-scale APIs manufacturers using natural yews as raw material and investing little in yew planting have been phased out gradually from the market, especially in the latest 3 years. However, it is relatively beneficial for some largest-scale paclitaxel injection manufacturers. With advantages of enough funds to cooperate with some APIs manufactures or develop their own yew planting areas, they are more competitive. However, China’s yew production amount has witnessed slight increase for three consecutive years from xx million in 2007, thanks to the development of greatly profitable APIs industry. Moreover, export value of paclitaxel APIs still takes up xx%, a large part in China’s total APIs production value. Because of intense competition in paclitaxel injection industry in China, paclitaxel injection producers have gained lower profit due to the declining paclitaxel injection price and continually high cost of yew in recent years. Paclitaxel injection price has declined in last 2 years in China mainly due to more supply into the market. Price of the paclitaxel injection for domestic manufacturers before 2008 kept at USDxx/dose ～ USDxx/dose, but currently it is USDxx/dose ～ USDxx/dose . Character of CCM' Report: The aim of this report is to provide powerful assistance to the strategy group and the management team in making correct decision as how to penetrate the ever-increasing China market and how to catch the maximum commercial opportunities. The report is formulated independently by CCM’s professional market researchers, based on the first-hand and primary data which are analyzed by scientific methodology, confirmed with both manufacturers/end users/traders and legal authorities, and presented in a logic way. Sample pages：
Website: http://www.cnchemicals.com Tel: +86-20-3761 6606
Email: econtact@cnchemicals.com Fax: +86-20-3761 6968
I Development of policy environment for paclitaxel injection in China By the end of Jun. 2010, many standards about environmental protection, production safety and application safety had been promulgated in China. Chinese government has strengthened pollution and quality control in paclitaxel industry to safeguard public health and eco-balance. Besides, Chinese government has adjusted export tax rebate rate time and again, aiming to achieve balance of supply and demand in domestic market. …….. Table I-2 Paclitaxel export tax rebate, 2005 to now Export tax rebate adjustments from Jan. 2005 to now Items of each HS code
Type HS code Paclitaxel
xx
Jan., 2005～Aug.,
Sep., 2008～
2008
Jul. 15 , 2010
th
Jul.15 , 2010-
th
xx%
xx%
xx%
xx%
xx%
xx%
xx%
xx%
xx%
xx%
xx%
xx%
xx%
xx%
xx%
10-deacetyl xx
paclitaxel Semi
xx
synthetic xx
(10-DAT) 7-epi-paclitaxel
paclitaxel 7-epi-10-deacety xx paclitaxel xx
xx
Paclitaxel injection
Source: State Administration of Taxation
……
IV-1.3 Sales value and market concentration of pharmaceutical distribution business in China ……
Regional disparity of China’s economy leads to the status quo of the pharmaceutical distribution business in different regions. According to a report issued by China Association of Pharmaceutical Commerce (CAPC) in 2009, pharmaceutical distribution is mainly concentrated in China’s relatively developed regions like East China, North China and South China accounting for xx% market share in 2009.
Figure IV-1.2.2 Market share of pharmaceutical distribution business in China by sales value, 2009
xx %
%
xx% % xx % xx % xx % xx
xx
xx
xx
xx
xx
xx
Source: China Association of Pharmaceutical Commerce
2003-now, the sales value and the market concentration of pharmaceutical distribution business increased year on year in China. …… The sales value of pharmaceutical distribution business has increased from USD xx million in 2003 to USD xx million in 2009 with CAGR of xx%, due to the rapid development of China’s economy and national health care reform. Table IV-1.3.1Sales value of pharmaceutical distribution companies in China, 2003-2009 Year
Sales value
(million, USD)
Growth Rate
2003
xx
xx%
2004
xx
xx%
2005
xx
xx%
2006
xx
xx%
2007
xx
xx%
2008
xx
xx%
2009
xx
xx%
xx%
-
CAGR，2003-2009 Source: CCM International